JPWO2021194608A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021194608A5 JPWO2021194608A5 JP2022554548A JP2022554548A JPWO2021194608A5 JP WO2021194608 A5 JPWO2021194608 A5 JP WO2021194608A5 JP 2022554548 A JP2022554548 A JP 2022554548A JP 2022554548 A JP2022554548 A JP 2022554548A JP WO2021194608 A5 JPWO2021194608 A5 JP WO2021194608A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- patient
- wandering
- item
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 22
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 239000003590 rho kinase inhibitor Substances 0.000 claims description 4
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical group C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 claims description 3
- 229960002435 fasudil Drugs 0.000 claims description 3
- 230000002085 persistent effect Effects 0.000 claims description 3
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 102000016252 Huntingtin Human genes 0.000 claims description 2
- 108050004784 Huntingtin Proteins 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 102100031822 Optineurin Human genes 0.000 claims description 2
- 101710131459 Optineurin Proteins 0.000 claims description 2
- 102000003890 RNA-binding protein FUS Human genes 0.000 claims description 2
- 108090000292 RNA-binding protein FUS Proteins 0.000 claims description 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims description 2
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 claims description 2
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims description 2
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims description 2
- 102000044159 Ubiquitin Human genes 0.000 claims description 2
- 108090000848 Ubiquitin Proteins 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000006996 mental state Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000001272 neurogenic effect Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 102000013498 tau Proteins Human genes 0.000 claims description 2
- 108010026424 tau Proteins Proteins 0.000 claims description 2
- 230000002618 waking effect Effects 0.000 claims description 2
- 206010038743 Restlessness Diseases 0.000 claims 5
- 150000002537 isoquinolines Chemical class 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical group C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 3
- 241001605695 Pareronia Species 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994527P | 2020-03-25 | 2020-03-25 | |
| US62/994,527 | 2020-03-25 | ||
| US202063005913P | 2020-04-06 | 2020-04-06 | |
| US63/005,913 | 2020-04-06 | ||
| PCT/US2021/012587 WO2021194608A1 (en) | 2020-03-25 | 2021-01-08 | Methods of treating proteinopathy- associated wandering |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518707A JP2023518707A (ja) | 2023-05-08 |
| JPWO2021194608A5 true JPWO2021194608A5 (de) | 2024-01-16 |
Family
ID=77855102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554548A Pending JP2023518707A (ja) | 2020-03-25 | 2021-01-08 | タンパク質症に関連する徘徊を治療する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11642352B2 (de) |
| EP (1) | EP4125879A4 (de) |
| JP (1) | JP2023518707A (de) |
| CN (1) | CN115916187A (de) |
| CA (1) | CA3170073A1 (de) |
| MX (1) | MX2022011518A (de) |
| WO (1) | WO2021194608A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3162382A1 (en) * | 2020-01-09 | 2021-07-15 | Thomas Macallister | Methods of treating cortical dementia associated wandering |
| WO2021216139A1 (en) * | 2020-04-23 | 2021-10-28 | Woolsey Pharmaceuticals, Inc | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| MX2023000600A (es) * | 2020-07-14 | 2023-02-13 | Woolsey Pharmaceuticals Inc | Metodos de tratamiento de proteinopatias. |
| WO2023086468A1 (en) * | 2021-11-12 | 2023-05-19 | Woolsey Pharmaceuticals, Inc. | Method of treating amyotrophic lateral sclerosis and dosing regimen for same |
| CA3236462A1 (en) | 2021-11-29 | 2023-06-01 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3464012B2 (ja) | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
| WO2000009133A1 (en) * | 1998-08-10 | 2000-02-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Sustained release oral preparations of fasudil hydrochloride |
| WO2005117896A1 (de) | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulierungen, die fasudil, eine matrix und einem mantel enthalten |
| WO2008036459A2 (en) | 2006-07-20 | 2008-03-27 | Borchardt Allen J | Inhibitors of rho kinase |
| JP2010501479A (ja) | 2006-08-10 | 2010-01-21 | トランスレーショナル ジェノミクス リサーチ インスティテュート | 学習および記憶を改善するための化合物 |
| WO2008021210A2 (en) | 2006-08-11 | 2008-02-21 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| CA2723472A1 (en) | 2008-05-12 | 2009-12-17 | Amnestix, Inc. | Compounds for rho kinase inhibition and for improving learning and memory |
| CN101612157A (zh) | 2008-06-26 | 2009-12-30 | 天津红日药业股份有限公司 | 法舒地尔诱导成年脑内源性神经干细胞再生的用途 |
| WO2013135596A1 (en) | 2012-03-12 | 2013-09-19 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis |
| WO2017195224A1 (en) | 2016-05-09 | 2017-11-16 | Istituto Superiore Di Sanita' | Rho gtpase activating bacterial toxins for use in the treatment of disorders of the central nervous system by mucosal administration |
| CA3162382A1 (en) * | 2020-01-09 | 2021-07-15 | Thomas Macallister | Methods of treating cortical dementia associated wandering |
| WO2021216139A1 (en) * | 2020-04-23 | 2021-10-28 | Woolsey Pharmaceuticals, Inc | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| MX2023000600A (es) * | 2020-07-14 | 2023-02-13 | Woolsey Pharmaceuticals Inc | Metodos de tratamiento de proteinopatias. |
-
2021
- 2021-01-08 CN CN202180036165.2A patent/CN115916187A/zh active Pending
- 2021-01-08 MX MX2022011518A patent/MX2022011518A/es unknown
- 2021-01-08 JP JP2022554548A patent/JP2023518707A/ja active Pending
- 2021-01-08 EP EP21776897.7A patent/EP4125879A4/de active Pending
- 2021-01-08 WO PCT/US2021/012587 patent/WO2021194608A1/en unknown
- 2021-01-08 CA CA3170073A patent/CA3170073A1/en active Pending
- 2021-01-08 US US17/144,802 patent/US11642352B2/en active Active
-
2023
- 2023-03-24 US US18/189,478 patent/US20230226073A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2046593A (en) | Pharmaceutical compositions comprising acyl-carnitine for the treatment of impaired cerebral metabolism | |
| US20220184075A1 (en) | Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching | |
| JP2009517393A (ja) | 不安症の治療方法 | |
| US11590107B2 (en) | Methods for treating neurological disorders with α1A-AR partial agonists | |
| CA2751638C (en) | Medicinal use of 5-benzylaminosalicylic acid derivative or its salt | |
| US20230255914A1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders | |
| JPWO2008090736A1 (ja) | アルツハイマー型認知症の予防及び治療のための医薬 | |
| EP2175850B1 (de) | Behandlung von angstzuständen | |
| JPWO2021194608A5 (de) | ||
| US11285167B2 (en) | Synergistic nutritional neuroprotective compositions for ameliorating neural dysfunction | |
| KR20190087572A (ko) | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
| JP2019516722A (ja) | 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用 | |
| CN110267657B (zh) | 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途 | |
| JP2022536331A (ja) | シヌクレイノパチーの治療 | |
| JP5386478B2 (ja) | パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 | |
| KR101503782B1 (ko) | 신경 세포사 억제제 | |
| JPH07507280A (ja) | （−）−メトリフォネート含有薬剤 | |
| EP4392033A1 (de) | Kombination eines nurr1-agonisten mit mindestens einem aldosteronantagonisten, einem insulinmodulator und einem sulfonylharnstoff | |
| KR20240022248A (ko) | 시린진을 포함하는 니코틴 중독 및 금단 증상의 예방, 개선 또는 치료용 조성물 | |
| OA20556A (en) | Treatment for synucleinopathies | |
| JP2023504876A (ja) | 薬物組成物、キット及びその応用 | |
| CN117338938A (zh) | 用于治疗中枢神经系统紊乱的组合疗法 | |
| KR20200099153A (ko) | 외상 후 증후군 장애의 치료 | |
| JP2002536326A (ja) | 冠状動脈インターベンションに伴う心臓血管事象の予防または軽減方法 | |
| JPS59167514A (ja) | 脳機能亢進剤組成物 |